Screening tests for thrombophilic patients: Which tests, for which patient, by whom, when, and why?

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 4, 1998, Pages 321-327

  De Moerloose, Philippe ^a   Bounameaux, Henri Ruti ^a   Mannucci, Pier M ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiphospholipid antibodies; Antithrombin; Homocysteinemia; Protein C; Protein S; Prothrombin; Resistance to activated protein C; Thrombophilia

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; DIAGNOSTIC TEST; DRUG DETERMINATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SCREENING TEST; THROMBOPHILIA; BLOOD EXAMINATION; MASS SCREENING; METHODOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; PROTEIN C DEFICIENCY; RISK ASSESSMENT; UTILIZATION REVIEW;

ACTIVATED PROTEIN C RESISTANCE; HEMATOLOGIC TESTS; HUMANS; MASS SCREENING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEIN C DEFICIENCY; RISK ASSESSMENT; THROMBOPHILIA;

EID: 0031595822     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996020     Document Type: Review

References (57)

1. British Society for Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990;43:703-710
2. Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: Predictive value of laboratory tests. Thromb Haemostas 1997;78: 75-78
3. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Thromb Haemostas 1995;73:151-161
4. Dahebäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulation response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008
5. Dahlbäck B. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-614
6. Van der Meer FJM, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemostas 1997;78:631-635
7. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994;369:64-67
8. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508
9. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg RP, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917
10. Siscovick DS, Schwartz SM, Rosendaal FR, Psaty BM. Thrombosis in the young: Effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemostas 1997;78:7-12
11. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-1134
12. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 1996;334:763-768
13. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemostas 1997;78:297-301
14. Jorquera J, Montoro JM, Angeles Fernandez M, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-1163
15. Trossaert M, Conard J, Horellou MH, et al. Modified APC-resistance assay for patients on oral anticoagulants. Lancet 1994; 344:1709
16. Engel H, Zwang L, van Vliet HH, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping for factor V Leiden. Thromb Haemostas 1996;75:267-269
17. 506 mutation. Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemostas 1997;77:436-439
18. Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
19. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemostas 1997;78:990-992
20. Lane D, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemostas 1996;76:651-662
21. Lane D, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemostas 1996;76:824-834
22. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency in the healthy population. Br J Haematol 1994; 87:106-112
23. Boyston TA, Lane DA. Antithrombin: Molecular basis of deficiency. Thromb Haemostas 1997;78:339-343
24. Saleun S, de Moerloose P, Bura A, Aiach M, Emmerich J. A novel nonsense mutation in the antithrombin gene (Cys-4;raStop) causing recurrent venous thrombosis. Blood Coag Fibrinolysis 1996;7:578-579
25. Bovill EG, Bauer KA, Dickermann JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989;73:712-717
26. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-2761
27. Esmon CT, Schwartz HP. An update on clinical and basic aspects on the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-148
28. Dahlbäck B. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 1995;77:1-43
29. Miletich JP, Sherman I, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-996
30. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemostas 1995; 73:87-93
31. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-1035
32. Reitsma PH. Protein C deficiency: From gene defects to disease. Thromb Haemostas 1997;78:344-350
33. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993;268:2872-2877
34. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BM. Inhibition of the intrinsic factor X activating complex by protein S: Evidence for specific binding of protein S to factor VIII. Blood 1995;86:1062-1071
35. Zöller B, Bernstdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:3518-3523
36. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemostas 1993;70:1067-1071
37. Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relation between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995;85:3524-3531
38. Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemostas 1997;78:351-356
39. Triplett DA. Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance. Thromb Res 1995;78:1-31
40. Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by antiphospholipid antibodies: Possible modes of action. Lupus 1994;3:223-228
41. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-2867
42. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemostas 1995;73:444-452
43. Di Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes and management. Blood 1996;87:3531-3544
44. Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease: A review of evidence and relevance. Thromb Haemostas 1997;78:520-522
45. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: Acquired conditions. Thromb Haemostas 1997;78:527-531
46. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17: 1157-1162
47. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10:111-113
48. Hirsh J, Prins MH, Samama M. Approach to the thrombophilic patient. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott; 1994:1543-1561
49. Bertina RM, van der Linden K, Engesser L, Muller HP, Brommer EJP. Hereditary heparin co-factor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987;57:196-200
50. Shigekiyo T, Uno Y, Tomonari A, et al. Type I plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemostas 1992;67:189-192
51. Santori MT, Patrassi GM, Theodoridis P, Perin A, Pielrogrande F, Girolami A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: A statistic-analysis in 20 kindreds. Blood Coag Fibrinolysis 1994;5:889-893
52. Koster T, Rosendaal FR, Vandenbroucke JP, Briët E. John Hageman's factor and deep-vein thrombosis: Leiden Thrombophilia study. Br J Haematol 1994;87:422-425
53. Rosendaal FR. Thrombosis in the young: Epidemilogy and risk factors. A focus on venous thrombosis. Thromb Haemostas 1997;78:1-6
54. Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coag Fibrinolysis 1996;7:507-514
55. Vandebroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptives users and pregnant women? Br Med J 1996;313:1127-1130
56. Desmarais S, de Moerloose P, Reber G, Minazio Ph, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996;347:1374-1375
57. Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemostas 1996;76:510-513